Methylation of the DPYD Promoter and Dihydropyrimidine Dehydrogenase Deficiency
نویسندگان
چکیده
منابع مشابه
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.
To the Editor: In their important article, Ezzeldin et al. (1) report a positive association between dihydropyrimidine dehydrogenase (DPD) deficiency and the DPD gene (DPYD) promoter hypermethylation in peripheral blood mononuclear cells of studied individuals. The authors focused on methylation in the individuals with the DPD deficiency, but did not elaborate on the impact of hypermethylation ...
متن کاملFamilial Deficiency of Dihydropyrimidine Dehydrogenase
Severe neurotoxicity due to 5-fluorouracil (FUra) has previously been described in a patient with familial pyrimidinemia. We now report the biochemical basis for both the pyrimidinemia and neurotoxicity in a patient we have recently studied. After administration of a "test" dose of FUra (25 mg/m2, 600 gCi 16-3HJFUra by intravenous bolus) to a patient who had previously developed neurotoxicity a...
متن کاملAberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
PURPOSE Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels. However, the regulatory mechanisms of DPD gene (DPYD) expression remain unclear. In ...
متن کاملComparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the uracil catabolic pathway, being critically important for inactivation of the commonly prescribed anti-cancer drug 5-fluorouracil (5-FU). DPD impairment leads to increased exposure to 5-FU and, in turn, increased anabolism of 5-FU to cytotoxic nucleotides, resulting in more severe clinical adverse effects. Numer...
متن کامل5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency
inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency Article abstract—Multifocal inflammatory leukoencephalopathy (MIL) is a cerebral demyelinating syndrome that develops after chemotherapy with 5-fluorouracil (5-FU) and levamisole. The authors report a patient who developed MIL after 5-FU administration not in association with levamisole. She was subsequently diagnos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2006
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-06-0549